Early-stage trial shows fecal microbiome capsules improve peanut tolerance in some participants

An early-phase clinical study examined whether oral capsules containing fecal microbiome material could help people with peanut allergy. Six volunteers received the treatment and were later exposed to small amounts of peanuts to assess tolerance.

Four months after the transplant, the participants showed increased ability to tolerate low‑dose peanut exposure compared with their baseline reactions. The improvement was observed in a subset of the small group, indicating a potential therapeutic effect.

Allergist‑immunologist Stephen Tilles, who was not involved in the research, described the findings as very exciting but cautioned that the approach is not yet ready for widespread clinical use. He emphasized the need for larger trials to confirm safety and efficacy.

The results were published in Science Translational Medicine, suggesting that fecal microbiome transplantation could become a novel strategy for managing food allergies pending further investigation.